Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.31 Bil Enterprise Value: 13.36 Bil PE Ratio: 70.93 PB Ratio: 2.84 GF Score: 62/100

Biomarin Pharmaceutical Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 03, 2021 / 05:00PM GMT
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Hi, everyone. This Eun Yang, biotech analyst at Jefferies. It is my pleasure to host a fireside chat with the J.J. Bienaime, Chairman and CEO of BioMarin; Hank Fuchs, President of Worldwide R&D; and Brian Mueller, Chief Financial Officer. Thanks all for joining us today.

So before we start Q&A with the management team, J.J. is going to give us a short overview, and then we'll go into Q&A. J.J.?

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Thank you, Eun. We appreciate the opportunity to speak with you today. As you know well, BioMarin is a fully integrated global leader in rare disease drugs, discovery, development, manufacturing and commercialization. Over the last few years, we have built a company designed for significant growth. Our global infrastructure incorporates a strong base business delivering close to $1 billion of revenues annually, a durable and scalable pipeline of innovative products and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot